China Financial Statements From 2010 to 2025

CPHI Stock  USD 0.29  0.00  0.000003%   
China Pharma financial statements provide useful quarterly and yearly information to potential China Pharma Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on China Pharma financial statements helps investors assess China Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting China Pharma's valuation are summarized below:
Gross Profit
349.3 K
Profit Margin
(0.70)
Market Capitalization
3.7 M
Enterprise Value Revenue
1.4421
Revenue
6.2 M
We have found one hundred twenty available fundamental signals for China Pharma Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of China Pharma Holdings prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 2.2 M. Enterprise Value is estimated to decrease to about 5.7 M

China Pharma Total Revenue

5.99 Million

Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.3 M, Interest Expense of 350.4 K or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 5.0E-4 or PTB Ratio of 0.26. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
  
Check out the analysis of China Pharma Correlation against competitors.

China Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18 M18.9 M64.3 M
Slightly volatile
Short and Long Term Debt Total7.4 M5.3 M8.8 M
Very volatile
Other Current Liabilities1.9 M1.8 M3.1 M
Slightly volatile
Total Current Liabilities9.2 M7.8 M10.4 M
Pretty Stable
Property Plant And Equipment Net13.2 M7.8 M16 M
Pretty Stable
Accounts Payable1.7 M1.1 M1.7 M
Slightly volatile
Cash2.8 M1.6 M2.9 M
Slightly volatile
Non Current Assets Total11.4 M12 M34.8 M
Slightly volatile
Cash And Short Term Investments2.8 M1.6 M2.9 M
Slightly volatile
Net Receivables566.3 K596.2 K14.1 M
Slightly volatile
Common Stock Total Equity37.5 K52.4 K42 K
Slightly volatile
Common Stock Shares Outstanding3.8 M3.9 M4.1 M
Slightly volatile
Liabilities And Stockholders Equity18 M18.9 M64.3 M
Slightly volatile
Non Current Liabilities Total3.5 M2.5 M4.9 M
Pretty Stable
Other Stockholder Equity20.4 M40.6 M24.4 M
Slightly volatile
Total Liabilities12.7 M10.4 M15.3 M
Pretty Stable
Property Plant And Equipment Gross44.9 M42.8 M25.6 M
Slightly volatile
Total Current Assets5.1 M5.4 M29.2 M
Slightly volatile
Short Term Debt4.4 M3.7 M4.5 M
Pretty Stable
Common Stock11.6 K12.2 K37.6 K
Pretty Stable
Current Deferred Revenue77.4 K81.5 K799.1 K
Slightly volatile
Inventory3.2 M3.4 M10.3 M
Slightly volatile
Other Current Assets152.3 K160.4 K1.9 M
Slightly volatile
Intangible Assets3.4 M3.3 M1.8 M
Slightly volatile
Other Liabilities718.4 K948.1 K696.9 K
Slightly volatile
Other Assets54.3 K57.1 K17.4 M
Slightly volatile
Property Plant Equipment17.9 M15.4 M17.8 M
Very volatile
Net Tangible AssetsM5.3 M56.3 M
Slightly volatile
Capital Surpluse26 M28.1 M24.2 M
Slightly volatile
Long Term Debt Total3.5 M1.9 M5.1 M
Slightly volatile
Short and Long Term Debt4.3 M2.8 M7.6 M
Slightly volatile
Net Invested Capital18.7 M10.8 M35.2 M
Slightly volatile
Capital Stock9.1 K9.6 K39.6 K
Slightly volatile

China Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense350.4 K383.6 K436.1 K
Very volatile
Selling General Administrative1.3 M1.3 MM
Slightly volatile
Total RevenueM6.3 M19.4 M
Slightly volatile
Other Operating Expenses12.3 M8.8 M13.5 M
Slightly volatile
Selling And Marketing Expenses667.2 K702.3 K2.4 M
Slightly volatile
Cost Of Revenue6.2 M6.6 M15.6 M
Slightly volatile
Non Operating Income Net Other4.9 K5.1 K140 K
Pretty Stable
Interest Income4.3 K4.6 K410.4 K
Slightly volatile
Reconciled Depreciation2.4 M2.4 MM
Slightly volatile

China Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.8 M2.3 M3.2 M
Pretty Stable
Depreciation1.9 M3.2 M2.4 M
Slightly volatile
End Period Cash Flow2.8 M1.6 M2.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.320.342.1 K
Slightly volatile
Dividend Yield5.0E-45.0E-46.0E-4
Slightly volatile
Days Sales Outstanding37.6739.66139
Slightly volatile
Average Payables870.6 K916.5 K1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.01060.01110.1556
Slightly volatile
Capex To Depreciation0.00460.00481.6633
Slightly volatile
EV To Sales0.820.862.1 K
Slightly volatile
Inventory Turnover1.481.761.8324
Slightly volatile
Days Of Inventory On Hand248215227
Slightly volatile
Payables Turnover14.368.689.6041
Very volatile
Sales General And Administrative To Revenue0.230.240.1941
Very volatile
Average Inventory3.4 M3.6 M6.8 M
Slightly volatile
Research And Ddevelopement To Revenue0.03880.03940.0324
Very volatile
Capex To Revenue0.00180.00190.0872
Slightly volatile
Cash Per Share0.470.40.6298
Slightly volatile
Payout Ratio0.050.05630.0614
Slightly volatile
Days Payables Outstanding68.9755.6374.8045
Slightly volatile
Intangibles To Total Assets0.210.20.0602
Slightly volatile
Current Ratio0.961.012.3504
Slightly volatile
Receivables Turnover5.019.538.186
Slightly volatile
Capex Per Share0.00370.00390.5487
Slightly volatile
Average Receivables710 K747.4 K12.3 M
Slightly volatile
Revenue Per Share2.262.384.3576
Slightly volatile
Interest Debt Per Share1.231.321.9964
Pretty Stable
Debt To Assets0.360.320.2931
Very volatile
Graham Number25.924.2427.1262
Very volatile
Operating Cycle438254344
Slightly volatile
Days Of Payables Outstanding68.9755.6374.8045
Slightly volatile
Dividend Payout Ratio0.050.05630.0614
Slightly volatile
Ebt Per Ebit1.291.011.8054
Very volatile
Quick Ratio0.360.381.5072
Slightly volatile
Net Income Per E B T3.112.961.4483
Slightly volatile
Cash Ratio0.220.190.2474
Pretty Stable
Cash Conversion Cycle352199300
Slightly volatile
Days Of Inventory Outstanding248215227
Slightly volatile
Days Of Sales Outstanding37.6739.66139
Slightly volatile
Fixed Asset Turnover1.121.181.868
Slightly volatile
Debt Ratio0.360.320.2931
Very volatile
Price Sales Ratio0.320.342.1 K
Slightly volatile
Asset Turnover0.470.490.3431
Slightly volatile

China Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 M2.4 M126.2 M
Slightly volatile
Enterprise Value5.7 MM133.2 M
Slightly volatile

China Fundamental Market Drivers

Cash And Short Term Investments1.4 M

China Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About China Pharma Financial Statements

Investors use fundamental indicators, such as China Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue81.5 K77.4 K
Total Revenue6.3 MM
Cost Of Revenue6.6 M6.2 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.24  0.23 
Research And Ddevelopement To Revenue 0.04  0.04 
Revenue Per Share 2.38  2.26 
Ebit Per Revenue(0.35)(0.37)

Currently Active Assets on Macroaxis

When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:
Check out the analysis of China Pharma Correlation against competitors.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.69)
Revenue Per Share
0.63
Quarterly Revenue Growth
(0.16)
Return On Assets
(0.18)
Return On Equity
(0.75)
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.